White Blood Cell Population May Serve as MS Biomarker
|
By LabMedica International staff writers Posted on 29 Jul 2019 |

Image: A CyTOF mass cytometer (Photo courtesy of Wikimedia Commons).
A discrete population of white blood cells was found to be present in samples taken from patients with multiple sclerosis (MS) and this group of cells may serve both diagnostic and therapeutic roles.
MS is among the class of chronic inflammatory diseases that is modulated by cytokine dysregulation. To better understand the link between cytokines and MS, investigators at the University of Zurich (Switzerland) sought to determine the characteristic cellular and cytokine polarization profile in patients with relapsing–remitting multiple sclerosis (RRMS) by using advanced high-dimensional single-cell mass cytometry (CyTOF).
CyTOF is a mass spectrometry technique based on inductively coupled plasma mass spectrometry and time of flight mass spectrometry used for the determination of the properties of cells (cytometry). In this approach, antibodies are conjugated with isotopically pure elements, and these antibodies are used to label cellular proteins. Cells are nebulized and sent in the form of a mist through an argon plasma, which ionizes the metal-conjugated antibodies. The metal signals are then analyzed by a time-of-flight mass spectrometer. The approach overcomes limitations of spectral overlap in flow cytometry by utilizing discrete isotopes as a reporter system instead of traditional fluorophores, which have broad emission spectra.
The use of CyTOF technology allowed the investigators to identify an expanded T helper cell subset in patients with MS, characterized by the expression of granulocyte–macrophage colony-stimulating factor and the C-X-C chemokine receptor type 4. This cellular signature, which included expression of very late antigen 4 in peripheral blood, was also enriched in the central nervous system of patients with relapsing–remitting multiple sclerosis. In independent validation cohorts, the investigators confirmed that this cell population was increased in patients with MS compared with other inflammatory and non-inflammatory conditions.
"We identified a specific population of white blood cells augmented in the peripheral blood of MS patients that have two properties characteristic of MS: They can move from the blood to the central nervous system and there they can cause inflammation of the nerve cells," said senior author Dr. Burkhard Becher, professor of experimental immunology at the University of Zurich. "Our data clearly indicate a stringent association of this signature to MS, and we believe that the identification of such an easily accessible biomarker brings important value for MS monitoring."
The report was published in the July 22, 2019, online edition of the journal Nature Medicine.
Related Links:
University of Zurich
MS is among the class of chronic inflammatory diseases that is modulated by cytokine dysregulation. To better understand the link between cytokines and MS, investigators at the University of Zurich (Switzerland) sought to determine the characteristic cellular and cytokine polarization profile in patients with relapsing–remitting multiple sclerosis (RRMS) by using advanced high-dimensional single-cell mass cytometry (CyTOF).
CyTOF is a mass spectrometry technique based on inductively coupled plasma mass spectrometry and time of flight mass spectrometry used for the determination of the properties of cells (cytometry). In this approach, antibodies are conjugated with isotopically pure elements, and these antibodies are used to label cellular proteins. Cells are nebulized and sent in the form of a mist through an argon plasma, which ionizes the metal-conjugated antibodies. The metal signals are then analyzed by a time-of-flight mass spectrometer. The approach overcomes limitations of spectral overlap in flow cytometry by utilizing discrete isotopes as a reporter system instead of traditional fluorophores, which have broad emission spectra.
The use of CyTOF technology allowed the investigators to identify an expanded T helper cell subset in patients with MS, characterized by the expression of granulocyte–macrophage colony-stimulating factor and the C-X-C chemokine receptor type 4. This cellular signature, which included expression of very late antigen 4 in peripheral blood, was also enriched in the central nervous system of patients with relapsing–remitting multiple sclerosis. In independent validation cohorts, the investigators confirmed that this cell population was increased in patients with MS compared with other inflammatory and non-inflammatory conditions.
"We identified a specific population of white blood cells augmented in the peripheral blood of MS patients that have two properties characteristic of MS: They can move from the blood to the central nervous system and there they can cause inflammation of the nerve cells," said senior author Dr. Burkhard Becher, professor of experimental immunology at the University of Zurich. "Our data clearly indicate a stringent association of this signature to MS, and we believe that the identification of such an easily accessible biomarker brings important value for MS monitoring."
The report was published in the July 22, 2019, online edition of the journal Nature Medicine.
Related Links:
University of Zurich
Latest Molecular Diagnostics News
- Liquid Biopsy Measures Tumor Burden and Identifies Small Cell Lung Cancer Subtypes
- Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
- Rapid Lab-Free UTI Test Enters First Use in Care Home Setting
- Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers
- New NGS Panel Detects AML Fusions at MRD-Level Sensitivity
- Spinal Fluid Liquid Biopsy May Help Clarify Uncertain Brain Tumor Findings
- Blood-Based Small RNA Assay Predicts Survival After Lung Cancer Treatment
- RNA Sequencing Assay Gains EU Certification for Solid Tumor Profiling
- Whole-Genome MRD Test Detects Traces of Cancer During and After Treatment
- Genomic Tissue Test Predicts Metastasis and Abiraterone Benefit in High-Risk Prostate Cancer
- Updated Framework Guides Assessment of Actionable Cancer Biomarkers
- Six-Gene Score Improves Prognosis Prediction in Acute Myeloid Leukemia
- Long-Read Sequencing Reveals Cancer-Driving Changes Missed by Conventional Testing
- Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use
- Donor-Derived DNA Testing May Reduce Biopsies in Kidney Transplant Monitoring
- AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read moreHematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read moreMicrobiology
view channel
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read morePathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more
AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. Routine health data, including blood... Read moreIndustry
view channel
CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. In Europe, meeting applicable EU IVDR requirements also means... Read more







